Dr. Chenghai Zhang, CEO of Mabgeek, stated, "We are excited to bring MG-K10 to the U.S. market and Phase III trials. Its unique profile positions it as a potential leader in the IL-4Rα-targeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback